News Flash!! Once-a-Day Triple NRTI WarningOctober 27, 2003 This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. Gilead Sciences, Inc., the manufacturer of the anti-HIV medication Tenofovir (Viread) today issued a "Dear Health Care Professional" letter (click here to view) describing high rates of virologic failure in patients treated with a "once-a-day" triple NRTI regimen that contains: Didanosine (ddI, Videx EC), Lamivudine (3TC, Epivir), and Tenofovir (Viread). This letter is somewhat technical and difficult to understand. Please call Roberto González at 206-957-1659 or 1-888-399-7837 if you would like further explanation.
This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.
|
|